Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Cell-Derived Flu Vaccine Reaches Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Protein Sciences' seasonal influenza vaccine FluBlok has typical immunity data but some manufacturing issues.

You may also be interested in...



Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says

J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee

Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says

J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee

Protein Sciences "Dumbfounded" After Committee Votes Down FluBlok

Cell-based seasonal influenza vaccine needs both additional safety data in general and considerably more efficacy data in older patients, FDA advisory panel says.

Topics

UsernamePublicRestriction

Register

PS068764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel